Table 5. Effect of spironolactone dosage (combined 2 mg/kg/day and 4 mg/kg/day) in 10 healthy purpose-bred Beagle dogs using a cross-over study design on RAS-Fingerprint^™ analytes at each sampling period at 12:00 (T2) 5-hours after oral dosing of spironolactone.

The sampling periods include two baseline sampling periods at Day 0 (D0) and Day 21 (D21) as well as following two seven-day treatment periods at Day 7 (D7) and Day 28 (D28). Data are presented as median (IQR) in pM/L for AngI, AngII, aldosterone, Ang1-7, Ang1-5, AngIII, AngIV, and PRA-S and as a ratio for ACE-S, AA2, and ALT-S. P value compares overall treatment to baseline at each specific timepoint (D0 vs. D7 and D21 vs. D28).

RAS Fingerprint™ analyte	D0	D7	Fold Difference	P-value	D21	D28	Fold Difference	P-value
AngI(1–10)	100.3 (60.3–121.3)	99.4 (633.7–125.0)	1.01	0.8	78.6 (61.0–120.0)	79.8 (59.5–97.8)	1.02	0.74
AngII(1–8)	37.0 (26.1–44.8)	38.4 (33.7–54.8)	1.04	0.68	34.2 (27.1–52.5)	38.6 (31.7–55.7)	1.13	0.58
Aldosterone	50.8 (19.8–68.2)	34.2 (29.0–74.4)	-1.49	0.97	11.2 (8.8–15.7)	33.5 (14.5–82.1)	2.99	0.11
Ang1-7	16.4 (9.5–21.4)	21.8 (11.6–30.1)	1.33	0.48	19.2 (14.3–33.3)	23.2 (18.7–26.7)	1.2	0.63
Ang1-5	27.1 (16.5–37.1)	21.9 (16.2–27.6)	-1.24	0.63	22.7 (17.7–28.0)	35.8 (31.0–52.5)	1.58	0.02
AngIII(2–8)	6.2 (4.4–10.5)	6.1 (5.3–11.8)	-1.02	0.68	5.8 (5.2–13.1)	5.2 (3.5–8.1)	-1.12	0.44
AngIV(3–8)	10.3 (9.0–16.6)	10.8 (8.6–11.9)	1.05	1	10.3 (8.1–20.5)	9.5 (7.9–15.7)	-1.08	0.68
PRA-S	141.9 (86.2–165.4)	137.1 (98.7–179.8)	-1.04	0.68	110.4 (88.7–172.5)	118.4 (88.9–149.3)	1.07	0.91
ACE-S	0.4 (0.4–0.5)	0.5 (0.4–0.6)	1.25	0.28	0.5 (0.5–0.5)	0.5 (0.5–0.6)	0	0.44
AA2	1.4 (0.5–1.6)	1 (0.7–1.3)	-1.4	0.85	0.4 (0.3–0.5)	1.0 (0.5–1.4)	2.5	0.06
ALT-S	0.3 (0.2–0.3)	0.2 (0.2–0.3)	-1.5	0.8	0.3 (0.3–0.3)	0.4 (0.3–0.4)	1.33	0.002